Abstract
Advances in genomic research and risk-directed therapy have led to improvements in the long-term survival and quality of life outcomes of patients with childhood acute lymphoblastic leukaemia (ALL). The application of next-generation sequencing technologies, especially transcriptome sequencing, has resulted in the identification of novel molecular subtypes of ALL with prognostic and therapeutic implications, as well as cooperative mutations that account for much of the heterogeneity in clinical responses observed among patients with specific ALL subtypes. In addition, germline genetic variants have been shown to influence the risk of developing ALL and/or the responses of non-malignant and leukaemia cells to therapy; shared pathways for drug activation and metabolism are implicated in treatment-related toxicity and drug sensitivity or resistance, depending on whether the genetic changes are germline, somatic or both. Indeed, although once considered a non-hereditary disease, genomic investigations of familial and sporadic ALL have revealed a growing number of genetic alterations or conditions that predispose individuals to the development of ALL and treatment-related second cancers. The identification of these genetic alterations holds the potential to direct genetic counselling, testing and possibly monitoring for the early detection of ALL and other cancers. Herein, we review these advances in our understanding of the genomic landscape of childhood ALL and their clinical implications.
Key points
-
Application of next-generation sequencing methods, especially transcriptome sequencing, has resulted in the discovery of many novel genetic rearrangements and mutations with prognostic and therapeutic implications in patients with acute lymphoblastic leukaemia (ALL).
-
A growing number of genetic conditions that predispose patients to develop ALL have been identified.
-
Pathogenic germline variants and common somatic mutations associated with ALL can affect the same genes (for example, PAX5, ETV6 and IKZF1).
-
Germline genetic variants influence the risk of developing ALL as well as the cellular response to anti-leukaemic therapy.
-
Germline genetic polymorphisms are usually retained in leukaemia cells; thus, they can affect drug responses in not only the non-malignant tissues of the host but also the leukaemia cells and, therefore, can affect the toxicities and anti-leukaemic activity of treatment.
-
Leukaemia cell genotype, pharmacogenetics and early treatment response assessed by minimal residual disease measurements should be used in concert to direct the treatment of patients with ALL.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pui, C.-H., Yang, J. J., Bhakta, N. & Rodriguez-Galindo, C. Global efforts toward the cure of childhood acute lymphoblastic leukaemia. Lancet Child Adolesc. Health 2, 440–454 (2018).
Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703–713 (2017).
Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321–327 (2018).
Ma, X. et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555, 371–376 (2018).
Moriyama, T., Relling, M. V. & Yang, J. J. Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood 125, 3988–3995 (2015).
Zhang, J. et al. Germline mutations in predisposition genes in pediatric cancer. N. Engl. J. Med. 373, 2336–2346 (2015).
Malkin, D., Nichols, K. E., Zelley, K. & Schiffman, J. D. Predisposition to pediatric and hematologic cancers: a moving target. Am. Soc. Clin. Oncol. Educ. Book https://doi.org/10.14694/EdBook_AM.2014.34.e44 (2014).
Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354, 166–178 (2006).
Roberts, K. G. & Mullighan, C. G. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat. Rev. Clin. Oncol. 12, 344–357 (2015).
Pui, C. H., Roberts, K. G., Yang, J. J. & Mullighan, C. G. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 17, 464–470 (2017).
Den Boer, M. L. et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 10, 125–134 (2009).
Harrison, C. J. et al. An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28, 1015–1021 (2014).
Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016).
Zhang, J. et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. Nat. Genet. 48, 1481–1489 (2016).
Yasuda, T. et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat. Genet. 48, 569–574 (2016).
Lilljebjorn, H. et al. Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B cell precursor acute lymphoblastic leukaemia. Nat. Commun. 7, 11790 (2016).
Liu, Y. F. et al. Genomic profiling of adult and pediatric B cell acute lymphoblastic leukemia. EBioMedicine 8, 173–183 (2016).
Gu, Z. et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat. Commun. 7, 13331 (2016).
Hirabayashi, S. et al. ZNF384-related fusion genes define a subgroup of childhood B cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica 102, 118–129 (2017).
Qian, M. et al. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 27, 185–195 (2017).
Zaliova, M. et al. ETV6/RUNX1-like acute lymphoblastic leukemia: a novel B cell precursor leukemia subtype associated with the CD27/CD44 immunophenotype. Genes Chromosomes Cancer 56, 608–616 (2017).
Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211–1218 (2017).
Hu, S. et al. Whole-genome noncoding sequence analysis in T cell acute lymphoblastic leukemia identifies oncogene enhancer mutations. Blood 129, 3264–3268 (2017).
Andersson, A. K. et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat. Genet. 47, 330–337 (2015).
Iacobucci, I. & Mullighan, C. G. Genetic basis of acute lymphoblastic leukemia. J. Clin. Oncol. 35, 975–983 (2017).
van der Veer, A. et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123, 1691–1698 (2014).
Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005–1015 (2014).
Stanulla, M. et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J. Clin. Oncol. 36, 1240–1249 (2018).
Perez-Andreu, V. et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat. Genet. 45, 1494–1498 (2013).
Yeoh, A. E. J. et al. Intensifying treatment of childhood B-lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival: results of malaysia-singapore ALL 2010 study. J. Clin Oncol. 36, 2726–2735 (2018).
Roberts, K. G. et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J. Clin. Oncol. 32, 3012–3020 (2014).
Jenkinson, S. et al. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 27, 41–47 (2013).
Gutierrez, A. et al. High frequency of PTEN, PI3K, and AKT abnormalities in T cell acute lymphoblastic leukemia. Blood 114, 647–650 (2009).
Petit, A. et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T cell acute lymphoblastic leukemia. Blood 131, 289–300 (2018).
Pui, C. H. et al. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with response-adapted therapy. Leukemia 31, 333–339 (2017).
Cazzaniga, G. et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T cell receptor and BCR/ABL1 methodologies. Haematologica 103, 107–115 (2018).
O’Connor, D. et al. Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J. Clin. Oncol. 36, 34–43 (2018).
Mullighan, C. G. et al. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood 126, 2896–2899 (2015).
Porter, C. C. et al. Recommendations for surveillance for children with leukemia-predisposing conditions. Clin. Cancer Res. 23, e14–e22 (2017).
McGee, R. B. & Nichols, K. E. Introduction to cancer genetic susceptibility syndromes. Hematology Am. Soc. Hematol. Educ. Program 2016, 293–301 (2016).
Godley, L. A. & Shimamura, A. Genetic predisposition to hematologic malignancies: management and surveillance. Blood 130, 424–432 (2017).
Feurstein, S., Drazer, M. W. & Godley, L. A. Genetic predisposition to leukemia and other hematologic malignancies. Semin. Oncol. 43, 598–608 (2016).
Auer, F. et al. Inherited susceptibility to pre B-ALL caused by germline transmission of PAX5 c.547 G>A. Leukemia 28, 1136–1138 (2014).
Shah, S. et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat. Genet. 45, 1226–1231 (2013).
Moriyama, T. et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 16, 1659–1666 (2015).
Noetzli, L. et al. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat. Genet. 47, 535–538 (2015).
Topka, S. et al. Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia. PLOS Genet. 11, e1005262 (2015).
Churchman, M. L. et al. Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia. Cancer Cell 33, 937–948 (2018).
Busslinger, M. Transcriptional control of early B cell development. Annu. Rev. Immunol. 22, 55–79 (2004).
Matthias, P. & Rolink, A. G. Transcriptional networks in developing and mature B cells. Nat. Rev. Immunol. 5, 497–508 (2005).
Nutt, S. L., Heavey, B., Rolink, A. G. & Busslinger, M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401, 556–562 (1999).
Urbanek, P., Wang, Z. Q., Fetka, I., Wagner, E. F. & Busslinger, M. Complete block of early B cell differentiation and altered patterning of the posterior midbrain in mice lacking Pax5/BSAP. Cell 79, 901–912 (1994).
Cobaleda, C., Jochum, W. & Busslinger, M. Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors. Nature 449, 473–477 (2007).
Kuiper, R. P. et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia 21, 1258–1266 (2007).
Mullighan, C. G. et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446, 758–764 (2007).
Nebral, K. et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 23, 134–143 (2009).
Zhang, M. Y. et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat. Genet. 47, 180–185 (2015).
Wang, L. C. et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 12, 2392–2402 (1998).
Green, S. M., Coyne, H. J. 3rd, McIntosh, L. P. & Graves, B. J. DNA binding by the ETS protein TEL (ETV6) is regulated by autoinhibition and self-association. J. Biol. Chem. 285, 18496–18504 (2010).
Olsson, L. & Johansson, B. Ikaros and leukaemia. Br. J. Haematol. 169, 479–491 (2015).
Martinelli, G. et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J. Clin. Oncol. 27, 5202–5207 (2009).
Mullighan, C. G. et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453, 110–114 (2008).
Roberts, K. G. et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J. Clin. Oncol. 35, 394–401 (2017).
Kuehn, H. S. et al. Loss of B cells in patients with heterozygous mutations in IKAROS. N. Engl. J. Med. 374, 1032–1043 (2016).
Yoshida, N. et al. Germline IKAROS mutation associated with primary immunodeficiency that progressed to T cell acute lymphoblastic leukemia. Leukemia 31, 1221–1223 (2017).
McKinnon, P. J. ATM and the molecular pathogenesis of ataxia telangiectasia. Annu. Rev. Pathol. 7, 303–321 (2012).
Morrell, D., Cromartie, E. & Swift, M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl Cancer Inst. 77, 89–92 (1986).
Suarez, F. et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J. Clin. Oncol. 33, 202–208 (2015).
Taylor, A. M., Metcalfe, J. A., Thick, J. & Mak, Y. F. Leukemia and lymphoma in ataxia telangiectasia. Blood 87, 423–438 (1996).
Gatti, R. & Perlman, S. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993).
Murphy, R. C. et al. Malignancies in pediatric patients with ataxia telangiectasia. Pediatr. Radiol. 29, 225–230 (1999).
Sandoval, C., Schantz, S., Posey, D. & Swift, M. Parotid and thyroid gland cancers in patients with ataxia-telangiectasia. Pediatr. Hematol. Oncol. 18, 485–490 (2001).
Swift, M., Morrell, D., Massey, R. B. & Chase, C. L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 325, 1831–1836 (1991).
van Os, N. J. et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin. Genet. 90, 105–117 (2016).
Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749–1753 (1995).
Hoyer, K. K. et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc. Natl Acad. Sci. USA 99, 14392–14397 (2002).
Roos, J. et al. Expression of TCL1 in hematologic disorders. Pathobiology 69, 59–66 (2001).
Varon, R., Demuth, I. & Chrzanowska, K. H. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993).
Chrzanowska, K. H., Gregorek, H., Dembowska-Baginska, B., Kalina, M. A. & Digweed, M. Nijmegen breakage syndrome (NBS). Orphanet J. Rare Dis. 7, 13 (2012).
Wolska-Kusnierz, B. et al. Nijmegen breakage syndrome: clinical and immunological features, long-term outcome and treatment options - a retrospective analysis. J. Clin. Immunol. 35, 538–549 (2015).
Nichols, K. E., Malkin, D., Garber, J. E., Fraumeni, J. F. Jr & Li, F. P. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol. Biomarkers Prev. 10, 83–87 (2001).
Comeaux, E. Q. & Mullighan, C. G. TP53 mutations in hypodiploid acute lymphoblastic leukemia. Cold Spring Harb. Perspect. Med. 7, a026286 (2017).
Holmfeldt, L. et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat. Genet. 45, 242–252 (2013).
Qian, M. et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J. Clin. Oncol. 36, 591–599 (2018).
Tabori, U. et al. Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin. Cancer Res. 23, e32–e37 (2017).
Wimmer, K. et al. Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’ (C4CMMRD). J. Med. Genet. 51, 355–365 (2014).
Kohlmann, W. & Gruber, S. B. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 2004).
Lavoine, N. et al. Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J. Med. Genet. 52, 770–778 (2015).
Vasen, H. F. et al. Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium “Care for CMMR-D” (C4CMMR-D). J. Med. Genet. 51, 283–293 (2014).
Ripperger, T. & Schlegelberger, B. Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome. Eur. J. Med. Genet. 59, 133–142 (2016).
Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206–2211 (2016).
Campbell, B. B. et al. Comprehensive analysis of hypermutation in human cancer. Cell 171, 1042–1056 (2017).
Westdorp, H. et al. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Lett. 403, 159–164 (2017).
Toledano, S. R. & Lange, B. J. Ataxia-telangiectasia and acute lymphoblastic leukemia. Cancer 45, 1675–1678 (1980).
Sandoval, C. & Swift, M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med. Pediatr. Oncol. 31, 491–497 (1998).
Eyre, J. A., Gardner-Medwin, D. & Summerfield, G. P. Leukoencephalopathy after prophylactic radiation for leukaemia in ataxia telangiectasia. Arch. Dis. Child 63, 1079–1080 (1988).
Yanofsky, R. A. et al. Ataxia-telangiectasia: atypical presentation and toxicity of cancer treatment. Can. J. Neurol. Sci. 36, 462–467 (2009).
Schulz, E. et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J. Med. Genet. 49, 422–428 (2012).
Churpek, J. E. et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer 122, 304–311 (2016).
Lage, H. & Dietel, M. Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. 125, 156–165 (1999).
Olivera Harris, M. et al. Mismatch repair-dependent metabolism of O6-methylguanine-containing DNA in Xenopus laevis egg extracts. DNA Repair (Amst.) 28, 1–7 (2015).
Shinsato, Y. et al. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget 4, 2261–2270 (2013).
Stritzelberger, J., Distel, L., Buslei, R., Fietkau, R. & Putz, F. Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine. Clin. Transl Oncol. 20, 508–516 (2018).
Bardelli, A. et al. Carcinogen-specific induction of genetic instability. Proc. Natl Acad. Sci. USA 98, 5770–5775 (2001).
Fink, D., Aebi, S. & Howell, S. B. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res. 4, 1–6 (1998).
Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
Moriyama, T. et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat. Genet. 48, 367–373 (2016).
Nishii, R. et al. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood 131, 2466–2474 (2018).
Meyer, J. A. et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45, 290–294 (2013).
Yang, J. J. et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J. Clin. Oncol. 33, 1235–1242 (2015).
Moriyama, T. et al. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet. Genomics 27, 236–239 (2017).
Tanaka, Y. et al. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J. 18, 275–280 (2018).
Tanaka, Y. et al. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia. Pharmacogenomics J. 15, 380–384 (2015).
Li, B. et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat. Med. 21, 563–571 (2015).
Tzoneva, G. et al. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature 553, 511–514 (2018).
Morten Tulstrup, M. G. et al. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia. Leukemia https://doi.org/10.1038/s41375-018-0245-3 (2018).
Vitellius, G., Trabado, S., Bouligand, J., Delemer, B. & Lombès, M. Pathophysiology of glucocorticoid signaling. Ann. Endocrinol. (Paris) 79, 98–106 (2018).
Kamdem, L. K. et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet. Genomics 18, 507–514 (2008).
Karol, S. E. et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood 126, 1770–1776 (2015).
French, D. et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood 111, 4496–4499 (2008).
Karol, S. E. et al. Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. Blood 127, 558–564 (2016).
Janke, L. J. et al. Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am. J. Pathol. 183, 19–25 (2013).
Kawedia, J. D. et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 117, 2340–2347 (2011).
Paugh, S. W. et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nat. Genet. 47, 607–614 (2015).
Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235–239 (2011).
Marke, R. et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B cell precursor acute lymphoblastic leukemia. Leukemia 30, 1599–1603 (2016).
Fernandez, C. A. et al. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 124, 1266–1276 (2014).
Liu, C. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 26, 2303–2309 (2012).
Kutszegi, N. et al. HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica 102, 1578–1586 (2017).
Liu, C. et al. Clinical and genetic risk factors for acute pancreatitis in patients with acute lymphoblastic leukemia. J. Clin. Oncol. 34, 2133–2140 (2016).
Witt, H. et al. Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat. Genet. 45, 1216–1220 (2013).
Lanvers-Kaminsky, C. Asparaginase pharmacology: challenges still to be faced. Cancer Chemother. Pharmacol. 79, 439–450 (2017).
Nakamura, A. et al. Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proc. Natl Acad. Sci. USA 115, E7776–E7785 (2018).
Diouf, B. et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313, 815–823 (2015).
Stock, W. et al. An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 101, 391–395 (2017).
Blanco, J. G. et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J. Clin. Oncol. 30, 1415–1421 (2012).
Pui, C.-H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938–2948 (2015).
Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470–480 (2009).
Seif, A. E. Pediatric leukemia predisposition syndromes: clues to understanding leukemogenesis. Cancer Genet. 204, 227–244 (2011).
German, J. Bloom’s syndrome. XX. The first 100 cancers. Cancer Genet. Cytogenet. 93, 100–106 (1997).
Quinn, E. & Nichols, K. E. Cancer predisposition syndromes associated with myeloid malignancy. Semin. Hematol. 54, 115–122 (2017).
Sanz, M. M., German, J. & Cunniff, C. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993).
Maloney, K. W., Taub, J. W., Ravindranath, Y., Roberts, I. & Vyas, P. Down syndrome preleukemia and leukemia. Pediatr. Clin. North Am. 62, 121–137 (2015).
Zwaan, M. C., Reinhardt, D., Hitzler, J. & Vyas, P. Acute leukemias in children with Down syndrome. Pediatr. Clin. North Am. 55, 53–70 (2008).
Xavier, A. C., Ge, Y. & Taub, J. Unique clinical and biological features of leukemia in Down syndrome children. Expert Rev. Hematol. 3, 175–186 (2010).
Mezei, G., Sudan, M., Izraeli, S. & Kheifets, L. Epidemiology of childhood leukemia in the presence and absence of Down syndrome. Cancer Epidemiol. 38, 479–489 (2014).
Latger-Cannard, V. et al. Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet J. Rare Dis. 11, 49 (2016).
Song, W. J. et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat. Genet. 23, 166–175 (1999).
Churpek, J. E. et al. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 126, 2484–2490 (2015).
West, A. H., Godley, L. A. & Churpek, J. E. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann. NY Acad. Sci 1310, 111–118 (2014).
Kutler, D. I. et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101, 1249–1256 (2003).
Alter, B. P., Greene, M. H., Velazquez, I. & Rosenberg, P. S. Cancer in Fanconi anemia. Blood 101, 2072 (2003).
Rosenberg, P. S., Greene, M. H. & Alter, B. P. Cancer incidence in persons with Fanconi anemia. Blood 101, 822–826 (2003).
Alter, B. P. Fanconi anemia and the development of leukemia. Best Pract. Res. Clin. Haematol. 27, 214–221 (2014).
Mehta, P. A. & Tolar, J. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993).
Stiller, C. A., Chessells, J. M. & Fitchett, M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br. J. Cancer 70, 969–972 (1994).
Friedman, J. M. in GeneReviews (eds Adam, M. P. et al.) (University of Washington, 1993).
Chang, T. Y., Dvorak, C. C. & Loh, M. L. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia. Blood 124, 2487–2497 (2014).
Niemeyer, C. M. RAS diseases in children. Haematologica 99, 1653–1662 (2014).
Cave, H. et al. Acute lymphoblastic leukemia in the context of RASopathies. Eur. J. Med. Genet. 59, 173–178 (2016).
Allanson, J. E. & Roberts, A. E. in GeneReviews (eds Adam, M. P. et al.) (University of Washington,1993).
Acknowledgements
The work of the authors is supported by US National Cancer Institute (NCI) grants CA21765 (to C.-H.P., K.E.N. and J.J.Y), R21 AI113490 (to K.E.N.) and P50 GM115279 (to C.-H.P. and J.J.Y.). C.-H.P., K.E.N. and J.J.Y. also receive support from the American Lebanese Syrian Associated Charities (ALSAC).
Review criteria
The information presented in this Review was compiled by searching PubMed for articles published between 1 January 2007 and 31 July 2018. The search terms used include “pediatric acute lymphoblastic leukaemia” in association with “germline mutations”, “somatic mutations”, “genotype” or “targeted therapy”. Selected relevant articles were reviewed, and references were checked for additional material, when appropriate. Only articles published in English were considered.
Reviewer information
Nature Reviews Clinical Oncology thanks G. Basso, A. Biondi, G. Henze and M. Stanulla for their contribution to the peer review of this work.
Author information
Authors and Affiliations
Contributions
C.-H.P., K.E.N. and J.J.Y. contributed equally to all stages of the preparation of this manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
About this article
Cite this article
Pui, CH., Nichols, K.E. & Yang, J.J. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 16, 227–240 (2019). https://doi.org/10.1038/s41571-018-0136-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0136-6
This article is cited by
-
Backtracking to the future: unraveling the origins of childhood leukemia
Leukemia (2024)
-
Acute lymphoblastic leukaemia
Nature Reviews Disease Primers (2024)
-
Increased risk of subsequent neoplasm after hematopoietic stem cell transplantation in 5-year survivors of childhood acute lymphoblastic leukemia
Blood Cancer Journal (2024)
-
Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment
Leukemia (2023)
-
A novel germline PAX5 single exon deletion in a pediatric patient with precursor B-cell leukemia
Leukemia (2023)